cb-839 and Neoplasms

cb-839 has been researched along with Neoplasms* in 4 studies

Reviews

1 review(s) available for cb-839 and Neoplasms

ArticleYear
Discovery and development of small molecule modulators targeting glutamine metabolism.
    European journal of medicinal chemistry, 2019, Feb-01, Volume: 163

    Cancer cells have been confirmed diverge significantly from normal cells on the metabolic properties. Energy production in cancer cells is abnormally dependent on the glycolysis pathway and other atypical metabolic characteristics such as increased fatty acid synthesis and increased rates of glutamine metabolism. Among these metabolic features of cancers, glutamine metabolism has been reported to be the main energy supply for the growth and viability of a potentially large subset of malignant tumors. In addition, the significance of glutamine metabolism in cancer cells derives from the ability of donate its nitrogen and carbon atoms for the synthesis of important biologically substances. During recent years, emerging evidences have proved the inhibitors targeting glutamine metabolism pathway could be efficient anticancer drugs. Therefore, in this review, we would briefly introduce the regulation of glutamine metabolism, and then summarize the recent advances of small molecule modulators targeting various nodes in glutamine signaling pathway. The current potential obstacles and future therapeutic perspectives in glutamine metabolism are also put forward in order to provide reference for the drug discovery of novel and potent glutamine metabolism modulators.

    Topics: Animals; Antineoplastic Agents; Drug Discovery; Energy Metabolism; Glutamine; Humans; Neoplasms

2019

Other Studies

3 other study(ies) available for cb-839 and Neoplasms

ArticleYear
Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
    European journal of medicinal chemistry, 2022, Jun-05, Volume: 236

    Glutaminase 1 (GLS1) is overexpressed in multiple types of malignant tumors and is viewed as a promising target in cancer therapy. Thus, the discovery for small-molecule GLS1 inhibitors is being urgent. Based on our previous study of C147, a potent GLS1 allosteric inhibitor yet with a limited metabolic stability, a structure-based optimization was carried out, with a series of novel GLS1 allosteric inhibitors rationally designed, synthesized and biologically evaluated. Such endeavor has culminated in the identification of 41e, a promising GLS1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles. 41e displayed robust GLS1 binding affinity, superior liver microsome metabolic stability, and moderate anti-tumor activity (TGI: 47.5%) in HCT116 xenograft model with no considerable toxicity in vivo. The mechanism underlying the anti-proliferative effect of 41e on HCT116 cells was studied, revealing that the compound blocked the glutamine metabolism, induced the production of ROS, and triggered apoptosis. These findings merit further investigation of 41e as a targeted cancer therapeutic.

    Topics: Animals; Apoptosis; Glutaminase; HCT116 Cells; Humans; Neoplasms

2022
Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
    Journal of medicinal chemistry, 2021, 04-22, Volume: 64, Issue:8

    The inhibition of glutaminase 1 (GLS1) represents a potential treatment of malignant tumors. Structural analysis led to the design of a novel series of macrocyclic GLS1 allosteric inhibitors. Through extensive structure-activity relationship studies, a promising candidate molecule

    Topics: Allosteric Site; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Glutaminase; Glycolysis; Half-Life; Humans; Macrocyclic Compounds; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Oxidative Phosphorylation; Rats; Structure-Activity Relationship

2021
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
    Journal of medicinal chemistry, 2019, 07-25, Volume: 62, Issue:14

    Tumors have evolved a variety of methods to reprogram conventional metabolic pathways to favor their own nutritional needs, including glutaminolysis, the first step of which is the hydrolysis of glutamine to glutamate by the amidohydrolase glutaminase 1 (GLS1). A GLS1 inhibitor could potentially target certain cancers by blocking the tumor cell's ability to produce glutamine-derived nutrients. Starting from the known GLS1 inhibitor bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide, we describe the medicinal chemistry evolution of a series from lipophilic inhibitors with suboptimal physicochemical and pharmacokinetic properties to cell potent examples with reduced molecular weight and lipophilicity, leading to compounds with greatly improved oral exposure that demonstrate in vivo target engagement accompanied by activity in relevant disease models.

    Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Drug Discovery; Glutaminase; Humans; Male; Mice, SCID; Molecular Docking Simulation; Neoplasms; Pyridazines; Thiadiazoles

2019